Description
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
This medication is designed to improve glycemic control in people with type 2 diabetes by targeting both the GIP and GLP-1 receptors. By stimulating these receptors, tirzepatide can increase insulin secretion and decrease glucagon secretion in a glucose-dependent manner, helping to lower blood sugar levels.
Clinical trials have shown promising results in terms of reducing HbA1c levels and body weight in individuals with type 2 diabetes. Tirzepatide is being studied in various dosages and formulations to determine its effectiveness, safety, and potential benefits for people with diabetes
NOTE: This product was prepared by chemical synthesis. Used only for research. Not for human use.
- tirzepatide
- tirzepatide weight loss
Production Capacity:
Not informed
Delivery Timeframe:
Not informed
Incoterms:
Not informedPackaging Details:
Not informed
More about
Synpeptide Co., Ltd
Not informed
Not informed
Not informed
Year
Established
Business type
- Industry / Manufacturer
Keywords
- semaglutide
- trizepatide
Contact and location
- Jiang kai
- +86 xxxxxxxx
- shanghai / shanghai | China